Radnostix Inc (INIS) Stock Price & Analysis
Radnostix Inc (INIS) rose 2.99% to USD 0.07 as of June 10, 2026 at 00:54 UTC, according to Nexqual real-time market data.
INIS last closed at USD 0.07; the session ranged USD 0.07–0.07 on volume of 129,790 shares. Market capitalization is $38.26M, with a 52-week range of USD 0.05–0.11 (OQB). Source: Nexqual, June 10, 2026 at 00:54 UTC.
Key Statistics (as of June 10, 2026 at 00:54 UTC)
| Price | USD 0.07 |
|---|---|
| Change | ▲ 2.99% (up) |
| Previous Close | USD 0.07 |
| Open | USD 0.07 |
| Day Range | USD 0.07 – 0.07 |
| 52-Week Range | USD 0.05 – 0.11 |
| Volume | 129,790 shares |
| Market Cap | $38.26M |
| Exchange | OQB |
Technical Analysis (INIS)
Nexqual's technical model rates INIS "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:54 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 45.98 (neutral) |
| vs SMA50 | Below (USD 0.08) |
| MACD | -0 (negative) |
Analyst Ratings (INIS)
Wall Street analysts rate INIS "None", per Nexqual as of June 10, 2026 at 00:54 UTC.
| Consensus Rating | None |
|---|
Earnings (INIS)
Source: Nexqual, June 10, 2026 at 00:54 UTC.
Financials & Fundamentals (INIS)
| Total Revenue | $12.21M |
|---|---|
| Revenue Growth (YoY) | -26.60% |
| Gross Margin | +55.87% |
| Operating Margin | -55.07% |
| Profit Margin | -17.55% |
| ROE | -61.36% |
| Debt / Equity | 332.13 |
| Current Ratio | 0.88 |
| Total Cash | $1.35M |
| Total Debt | $8.79M |
| Free Cash Flow | $371,638 |
Source: Nexqual, June 10, 2026 at 00:54 UTC.
Financial Health Score (INIS)
Nexqual rates Radnostix Inc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:54 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Critical — $1M cash vs $9M debt |
| Cash Flow | Mixed — FCF $372K, slim 4.9% margin |
| Efficiency | Critical — ROE -61%, ROA -7.9% |
Ownership (INIS)
| Insider Ownership | +73.47% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 529.13M |
| Float | 332.28M |
Source: Nexqual, June 10, 2026 at 00:54 UTC.
From Radnostix Inc's Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Radnostix, Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally.
- It operates through five segments: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products.
- The Theranostics Products segment produces and distributes Iodine-131 generic drug product and various isotopically pure radiochemicals for medical, industrial, and research applications.
- The Cobalt Products segment produces cobalt-60 products and services, the fabrication of cobalt-60 sealed sources for radiation therapy, industrial and medical applications, and recycling of expended cobalt-60 sources.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATVK | Ameritek Ventures | USD 10.21 | ▲ 0.1% |
| MYMX | MYMETICS CORPORATION | USD 0 | ▲ 0% |
| HMGN | HEMAGEN DIAGNOSTICS INC | USD 0 | ▲ 0% |
| CHUC | Charlie's Holdings, Inc. | USD 0.22 | ▼ 10.47% |
| CRVW | Careview Communications, Inc. | USD 0.05 | ▲ 9.8% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:54 UTC. This page is informational and not investment advice.